HeartSciences Inc.
Financial highlights
| Metric | FY 04/30/25 | FY 04/30/24 | FY 04/30/23 | FY 04/30/22 | FY 04/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4,350 | $18,600 | $5,150 | $14,373 | — |
| Cost of revenue | $1,880 | $6,081 | $2,796 | $7,890 | — |
| Gross profit | $2,470 | $12,519 | $2,354 | $6,483 | — |
| Selling, general & administrative | $4.0M | $3.4M | $3.7M | $1.7M | — |
| Research and development | $4.4M | $2.9M | $2.5M | $3.0M | — |
| Operating expenses | $8.4M | $6.3M | $6.1M | $4.7M | — |
| Operating income | -$8.4M | -$6.3M | -$6.1M | -$4.7M | — |
| Interest expense | $500,453 | $354,080 | $243,174 | $371,619 | — |
| Net income | -$8.8M | -$6.6M | -$6.4M | -$4.8M | — |
| Balance Sheet | |||||
| Cash and equivalents | $1.1M | $5.8M | $1.7M | $918,260 | — |
| Current assets | $2.2M | $7.4M | $2.7M | $1.9M | — |
| Total assets | $4.2M | $9.5M | $3.3M | $2.1M | — |
| Current liabilities | $3.7M | $1.8M | $1.8M | $3.5M | — |
| Total liabilities | $4.0M | $2.2M | $3.1M | $8.1M | — |
| Stockholders' equity | $205,171 | $7.3M | $230,557 | -$6.1M | -$1.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$7.4M | -$6.1M | -$5.8M | -$3.6M | — |
| Depreciation and amortization | $37,599 | $27,892 | $26,915 | $26,566 | — |
| Stock-based compensation | $249,884 | $405,025 | $248,307 | $68,396 | — |
| Capital expenditure | $3,157 | $64,455 | $18,308 | $1,932 | — |
| Free cash flow | -$7.4M | -$6.1M | -$5.8M | -$3.6M | — |
| Dividends paid | $0 | $0 | $0 | $0 | — |
Shares outstanding 3.2M · Free float 94.8%
Annual filing data through FY ended April 30, 2025; float as of July 13, 2026.